Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Single-Arm Study of Tisagenlecleucel in Relapsed/Refractory DLBCL (Japan)
jRCT1080223094Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Novartis. Started Jan 2016; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT1080223094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223094.